(Q40174720)

18 September 2017

1 reference

title

Clinical pharmacokinetics of labetalol (English)

1 reference

18 September 2017

Clinical Pharmacokinetics of Labetalol (English)

1 reference

10.2165/00003088-198409020-00003

Crossref

DOI

https://api.crossref.org/works/10.2165/00003088-198409020-00003

10 October 2023

1 reference

10.2165/00003088-198409020-00003

https://api.crossref.org/works/10.2165/00003088-198409020-00003

10 October 2023

1 reference

1

J. J. McNeil

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6370541

10 October 2023

author name string

W. J. Louis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6370541

10 October 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6370541

10 October 2023

publication date

1 March 1984

1 reference

Clinical Pharmacokinetics

18 September 2017

1 reference

18 September 2017

9

1 reference

18 September 2017

2

1 reference

18 September 2017

157-167

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-198409020-00003

18 September 2017

0 references

cites work

Pharmacological effects of labetalol in man

1 reference

12 December 2020

Metabolism of labetalol by animals and man.

1 reference

12 December 2020

Determination of labetalol in human plasma by high-performance liquid chromatography

1 reference

12 December 2020

Labetalol steady-state pharmacokinetics in hypertensive patients

1 reference

12 December 2020

Elimination kinetics of labetalol in severe renal failure

1 reference

12 December 2020

Use of labetalol in the treatment of severe hypertension during pregnancy

1 reference

12 December 2020

Clinical and pharmacokinetic studies on the alpha- and beta-blocking drug labetalol

1 reference

12 December 2020

Effect of food on the bioavailability of labetalol

1 reference

12 December 2020

Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension

1 reference

12 December 2020

A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension

1 reference

12 December 2020

Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension

1 reference

12 December 2020

Drug Kinetics and Hepatic Blood Flow

1 reference

12 December 2020

Haemodynamic effects of long-term oral labetalol

1 reference

12 December 2020

Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension

1 reference

12 December 2020

[3H]-guanfacine: a radioligand that selectively labels high affinity alpha2-adrenoceptor sites in homogenates of rat brain.

1 reference

12 December 2020

Pharmacological basis for antihypertensive effects of intravenous labetalol

1 reference

12 December 2020

Closing remarks: current status of labetalol

1 reference

12 December 2020

The short term effects of propranolol, atenolol and labetalol on antipyrine kinetics in normal subjects

1 reference

12 December 2020

Mean steady-state plasma concentrations of labetalol in patients undergoing antihypertensive therapy

1 reference

12 December 2020

Labetalol in resistant hypertension

1 reference

12 December 2020

Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility [letter]

1 reference

12 December 2020

Acute haemodynamic effects of labetalol and its subsequent use of an oral hypotensive agent

1 reference

12 December 2020

Decreased first-pass metabolism of labetalol in chronic liver disease

1 reference

12 December 2020

Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations

1 reference

12 December 2020

Double-blind trial of labetalol

1 reference

12 December 2020

An analysis of the blood pressure response to labetalol in hypertensive patients

1 reference

12 December 2020

Coarctation in children. Controlled hypotension using labetalol and halothane

1 reference

12 December 2020

Labetalol in the treatment of patients with hypertension and renal function impairment

1 reference

12 December 2020

Labetalol in hypertension

1 reference

12 December 2020

Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise

1 reference

12 December 2020

Labetalol compared with prindolol plus hydraliazine in the treatment of hypertension: a double-blind cross-over study

1 reference

12 December 2020

Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism

1 reference

12 December 2020

Affinity of labetalol for ocular melanin.

1 reference

12 December 2020

Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects

1 reference

12 December 2020

Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects

1 reference

12 December 2020

The effects of labetalol (AH 5158) on adrenergic transmission in the cat spleen

1 reference

12 December 2020

Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol

1 reference

12 December 2020

Pharmacokinetics of labetalol in healthy volunteers

1 reference

12 December 2020

Bioavailability of labetalol increases with age.

1 reference

12 December 2020

Letter: Intravenous labetalol in severe hypertension

1 reference

12 December 2020

Labetalol disposition and concentration-effect relationships during pregnancy

1 reference

12 December 2020

Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol

1 reference

12 December 2020

Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors

1 reference

12 December 2020

The alpha- and beta-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues

1 reference

12 December 2020

Acute management of severe hypertension with oral labetalol

1 reference

12 December 2020

10.2165/00003088-198409020-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

18 September 2017

0 references

1 reference